Literature DB >> 32236819

The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study.

Bruno Madeo1, Sara De Vincentis2,3, Andrea Repaci4, Paola Altieri4, Valentina Vicennati4, Elda Kara3,5, Fabio Vescini5, Pierluigi Amadori6, Antonio Balestrieri7, Uberto Pagotto4, Manuela Simoni2,3, Vincenzo Rochira2,3.   

Abstract

PURPOSE: The diagnosis of primary hyperparathyroidism (PHPT) and chronic hypoparathyroidism (HypoPT) is still challenging, especially in patients asymptomatic or with non-classical phenotypes and for physicians not skilled in calcium-phosphorous (Ca-P) disorders. The serum calcium/phosphorous (Ca/P) ratio has been proposed as accurate index to identify PHPT, while it has never been tested in HypoPT. The aim of this study is to investigate the diagnostic power of the serum Ca/P ratio in the diagnosis of primary parathyroid dysfunctions (both PHPT and HypoPT) in a large series of data.
METHODS: A multicentric, retrospective, cross-sectional study (ClinicalTrials.gov: NCT03747029) was carried out including 432 PHPT patients and 217 HypoPT patients compared with 389 controls. Serum Ca, P, creatinine, parathyroid hormone and 25OH-vitamin D were collected. Serum Ca and P were expressed in mmol/L. Ca/P diagnostic performance was evaluated by receiver operating characteristic (ROC) curve, sensitivity, specificity and accuracy.
RESULTS: The Ca/P ratio was significantly higher in PHPT and lower in HypoPT patients than controls (p < 0.0001). At ROC curve analysis, the Ca/P ratio above 2.55 was defined to identify PHPT patients (sensitivity 85.7%, specificity 85.3%) and below 1.78 to identify HypoPT patients (sensitivity 88.2%, specificity 87.9%).
CONCLUSIONS: The Ca/P ratio is a highly accurate index to identify PHPT when Ca/P is above 2.55 and HypoPT when it is below 1.78. These results demonstrate the reliability of this index to rule in/out primary parathyroid dysfunctions and remark the importance of measuring serum P in clinical practice.

Entities:  

Keywords:  Disorders of calcium/phosphate metabolism; Hyperparathyroidism; Hypoparathyroidism; Parathyroid-related disorders; Screening

Mesh:

Substances:

Year:  2020        PMID: 32236819     DOI: 10.1007/s12020-020-02276-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  5 in total

1.  Diagnostic performance of the calcium/phosphate ratio for primary hyperparathyroidism in southwest China.

Authors:  Mengting Yin; Qianhui Liu; Qingzhong Wang; Yong He; Haolan Song; Xin Nie; Guixing Li
Journal:  Endocr Connect       Date:  2021-10-25       Impact factor: 3.335

Review 2.   Misdiagnosis of brown tumour caused by primary hyperparathyroidism: a case report with literature review.

Authors:  Yanchun Zhong; Yuxi Huang; Jiaquan Luo; Yongjun Ye
Journal:  BMC Endocr Disord       Date:  2022-03-14       Impact factor: 2.763

Review 3.  Phosphate Metabolism and Pathophysiology in Parathyroid Disorders and Endocrine Tumors.

Authors:  Guido Zavatta; Paola Altieri; Giulia Vandi; Valentina Vicennati; Uberto Pagotto; Fabio Vescini
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

4.  Use of Parathyroid Function Index and Wisconsin Index to Differentiate Primary Hyperparathyroidism From Secondary Hyperparathyroidism: A Case-Control Study.

Authors:  Murat Bulut Özkan; Veysel Barış Turhan
Journal:  Cureus       Date:  2022-03-10

Review 5.  Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach.

Authors:  Guido Zavatta; Bart L Clarke
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.